O	0	11	Involvement	Involvement	NN	B-NP
O	12	14	of	of	IN	B-PP
O	15	17	de	de	FW	B-NP
O	18	22	novo	novo	FW	I-NP
O	23	31	ceramide	ceramide	NN	I-NP
O	32	41	synthesis	synthesis	NN	I-NP
O	42	44	in	in	IN	B-PP
O	45	58	radiocontrast	radiocontrast	NN	B-NP
O	58	59	-	-	HYPH	B-NP
O	59	66	induced	induce	VBN	I-NP
B-Cell	67	72	renal	renal	JJ	I-NP
I-Cell	73	80	tubular	tubular	JJ	I-NP
I-Cell	81	85	cell	cell	NN	I-NP
O	86	92	injury	injury	NN	I-NP
O	92	93	.	.	.	O

O	94	96	We	We	PRP	B-NP
O	97	105	reported	report	VBD	B-VP
O	106	116	previously	previously	RB	B-ADVP
O	117	121	that	that	IN	B-SBAR
O	122	129	various	various	JJ	B-NP
O	130	143	radiocontrast	radiocontrast	NN	I-NP
O	144	149	media	medium	NNS	I-NP
O	150	155	cause	cause	VBP	B-VP
O	156	165	apoptosis	apoptosis	NN	B-NP
O	166	168	in	in	IN	B-PP
O	169	176	porcine	porcine	JJ	B-NP
B-Cell	177	185	proximal	proximal	JJ	I-NP
I-Cell	186	193	tubular	tubular	JJ	I-NP
I-Cell	194	195	(	(	(	O
I-Cell	195	198	LLC	LLC	NN	O
I-Cell	198	199	-	-	HYPH	O
I-Cell	199	201	PK	PK	NN	B-NP
I-Cell	201	202	(	(	(	O
I-Cell	202	203	1	1	CD	B-NP
I-Cell	203	204	)	)	)	O
I-Cell	204	205	)	)	)	O
I-Cell	206	211	cells	cell	NNS	B-NP
O	211	212	,	,	,	O
O	213	215	in	in	IN	B-PP
O	216	221	which	which	WDT	B-NP
O	222	231	reduction	reduction	NN	B-NP
O	232	234	in	in	IN	B-PP
O	235	236	B	B	NN	B-NP
O	236	237	-	-	HYPH	B-NP
O	237	241	cell	cell	NN	I-NP
O	242	250	lymphoma	lymphoma	NN	I-NP
O	251	252	(	(	(	O
O	252	255	Bcl	Bcl	NN	B-NP
O	255	256	)	)	)	O
O	256	257	-	-	HYPH	B-NP
O	257	258	2	2	CD	I-NP
O	259	269	expression	expression	NN	I-NP
O	270	273	and	and	CC	O
O	274	281	caspase	caspase	NN	B-NP
O	281	282	-	-	HYPH	O
O	282	283	3	3	CD	B-NP
O	284	294	activation	activation	NN	I-NP
O	295	298	are	be	VBP	B-VP
O	299	309	implicated	implicate	VBN	I-VP
O	309	310	.	.	.	O

O	311	313	In	In	IN	B-PP
O	314	317	the	the	DT	B-NP
O	318	325	present	present	JJ	I-NP
O	326	331	study	study	NN	I-NP
O	331	332	,	,	,	O
O	333	335	we	we	PRP	B-NP
O	336	348	investigated	investigate	VBD	B-VP
O	349	350	a	a	DT	B-NP
O	351	355	role	role	NN	I-NP
O	356	359	for	for	IN	B-PP
O	360	368	ceramide	ceramide	NN	B-NP
O	369	371	in	in	IN	B-PP
O	372	385	radiocontrast	radiocontrast	NN	B-NP
O	386	391	media	medium	NNS	I-NP
O	391	392	-	-	HYPH	O
O	392	399	induced	induce	VBN	B-NP
O	400	409	apoptosis	apoptosis	NN	I-NP
O	410	412	in	in	IN	B-PP
B-Cell	413	418	renal	renal	JJ	B-NP
I-Cell	419	426	tubular	tubular	JJ	I-NP
I-Cell	427	432	cells	cell	NNS	I-NP
O	432	433	.	.	.	O

B-Cell	434	437	LLC	LLC	NN	B-NP
I-Cell	437	438	-	-	HYPH	O
I-Cell	438	440	PK	PK	NN	B-NP
I-Cell	440	441	(	(	(	O
I-Cell	441	442	1	1	CD	B-NP
I-Cell	442	443	)	)	)	O
I-Cell	444	449	cells	cell	NNS	B-NP
O	450	454	were	be	VBD	B-VP
O	455	462	exposed	expose	VBN	I-VP
O	463	465	to	to	TO	B-PP
O	466	479	radiocontrast	radiocontrast	NN	B-NP
O	480	485	media	medium	NNS	I-NP
O	486	489	for	for	IN	B-PP
O	490	492	30	30	CD	B-NP
O	493	496	min	min	NN	I-NP
O	496	497	,	,	,	O
O	498	506	followed	follow	VBN	B-VP
O	507	509	by	by	IN	B-PP
O	510	520	incubation	incubation	NN	B-NP
O	521	524	for	for	IN	B-PP
O	525	527	24	24	CD	B-NP
O	528	529	h	h	NN	I-NP
O	530	532	in	in	IN	B-PP
O	533	539	normal	normal	JJ	B-NP
O	540	546	medium	medium	NN	I-NP
O	546	547	.	.	.	O

B-Cell	548	552	Cell	Cell	NN	B-NP
O	553	562	viability	viability	NN	I-NP
O	563	566	was	be	VBD	B-VP
O	567	575	assessed	assess	VBN	I-VP
O	576	578	by	by	IN	B-PP
O	579	580	2	2	CD	B-NP
O	580	581	-	-	HYPH	O
O	581	582	(	(	(	O
O	582	583	2	2	CD	B-NP
O	583	584	-	-	HYPH	I-NP
O	584	591	methoxy	methoxy	NN	I-NP
O	591	592	-	-	HYPH	B-NP
O	592	593	4	4	CD	I-NP
O	593	594	-	-	HYPH	I-NP
O	594	605	nitrophenyl	nitrophenyl	NN	I-NP
O	605	606	)	)	)	O
O	606	607	-	-	HYPH	B-NP
O	607	608	3	3	CD	I-NP
O	608	609	-	-	HYPH	O
O	609	610	(	(	(	O
O	610	611	4	4	CD	B-NP
O	611	612	-	-	HYPH	I-NP
O	612	623	nitrophenyl	nitrophenyl	NN	I-NP
O	623	624	)	)	)	O
O	624	625	-	-	HYPH	B-NP
O	625	626	5	5	CD	I-NP
O	626	627	-	-	HYPH	O
O	627	628	(	(	(	O
O	628	629	2	2	CD	B-NP
O	629	630	,	,	,	O
O	630	631	4	4	CD	B-NP
O	631	632	-	-	HYPH	I-NP
O	632	645	disulfophenyl	disulfophenyl	NN	I-NP
O	645	646	)	)	)	O
O	646	647	-	-	HYPH	B-NP
O	647	649	2H	2H	NN	I-NP
O	649	650	-	-	HYPH	B-NP
O	650	661	tetrazolium	tetrazolium	NN	I-NP
O	662	672	monosodium	monosodium	NN	I-NP
O	673	677	salt	salt	NN	I-NP
O	678	683	assay	assay	NN	I-NP
O	683	684	,	,	,	O
O	685	690	while	while	IN	B-SBAR
O	691	700	apoptosis	apoptosis	NN	B-NP
O	701	704	was	be	VBD	B-VP
O	705	715	determined	determine	VBN	I-VP
O	716	718	by	by	IN	B-PP
O	719	727	terminal	terminal	JJ	B-NP
O	728	744	deoxynucleotidyl	deoxynucleotidyl	NN	I-NP
O	745	756	transferase	transferase	NN	I-NP
O	756	757	-	-	HYPH	B-VP
O	757	765	mediated	mediate	VBN	B-NP
O	766	770	dUTP	dUTP	NN	I-NP
O	771	775	nick	nick	NN	I-NP
O	776	779	end	end	NN	I-NP
O	780	788	labeling	labeling	NN	I-NP
O	789	794	stain	stain	NN	I-NP
O	794	795	.	.	.	O

O	796	813	Immunofluorescent	Immunofluorescent	JJ	B-NP
O	814	820	stains	stain	NNS	I-NP
O	821	825	were	be	VBD	B-VP
O	826	835	performed	perform	VBN	I-VP
O	836	841	using	use	VBG	B-VP
O	842	852	antibodies	antibody	NNS	B-NP
O	853	860	against	against	IN	B-PP
O	861	875	phosphorylated	phosphorylate	VBN	B-NP
O	876	879	Akt	Akt	NN	I-NP
O	880	881	(	(	(	O
O	881	885	pAkt	pAkt	NN	B-NP
O	885	886	)	)	)	O
O	887	890	and	and	CC	O
O	891	895	cAMP	cAMP	NN	B-NP
O	896	904	response	response	NN	I-NP
O	905	912	element	element	NN	I-NP
O	913	920	binding	binding	NN	I-NP
O	921	928	protein	protein	NN	I-NP
O	929	930	(	(	(	O
O	930	934	CREB	CREB	NN	B-NP
O	934	935	)	)	)	O
O	936	937	(	(	(	O
O	937	942	pCREB	pCREB	NN	B-NP
O	942	943	)	)	)	O
O	943	944	,	,	,	O
O	945	948	and	and	CC	O
O	949	957	ceramide	ceramide	NN	B-NP
O	957	958	.	.	.	O

O	959	962	The	The	DT	B-NP
O	963	967	mRNA	mRNA	NN	I-NP
O	968	978	expression	expression	NN	I-NP
O	979	982	and	and	CC	O
O	983	990	protein	protein	NN	B-NP
O	991	998	content	content	NN	I-NP
O	999	1001	of	of	IN	B-PP
O	1002	1005	Bcl	Bcl	NN	B-NP
O	1005	1006	-	-	HYPH	B-NP
O	1006	1007	2	2	CD	I-NP
O	1008	1012	were	be	VBD	B-VP
O	1013	1023	determined	determine	VBN	I-VP
O	1024	1026	by	by	IN	B-PP
O	1027	1034	reverse	reverse	JJ	B-NP
O	1035	1048	transcriptase	transcriptase	NN	I-NP
O	1048	1049	-	-	HYPH	I-NP
O	1049	1059	polymerase	polymerase	NN	I-NP
O	1060	1065	chain	chain	NN	I-NP
O	1066	1074	reaction	reaction	NN	I-NP
O	1075	1078	and	and	CC	O
O	1079	1085	enzyme	enzyme	NN	B-NP
O	1086	1097	immunoassay	immunoassay	NN	I-NP
O	1097	1098	,	,	,	O
O	1099	1111	respectively	respectively	RB	B-ADVP
O	1111	1112	.	.	.	O

O	1113	1115	In	In	FW	B-NP
O	1116	1120	vivo	vivo	FW	I-NP
O	1121	1126	model	model	NN	I-NP
O	1127	1129	of	of	IN	B-PP
O	1130	1138	contrast	contrast	NN	B-NP
O	1138	1139	-	-	HYPH	B-NP
O	1139	1146	induced	induce	VBN	I-NP
B-Organ	1147	1152	renal	renal	JJ	I-NP
O	1153	1159	injury	injury	NN	I-NP
O	1160	1163	was	be	VBD	B-VP
O	1164	1171	induced	induce	VBN	I-VP
O	1172	1174	in	in	IN	B-PP
O	1175	1179	mice	mouse	NNS	B-NP
O	1180	1184	with	with	IN	B-PP
O	1185	1195	unilateral	unilateral	JJ	B-NP
B-Organ	1196	1201	renal	renal	JJ	I-NP
O	1202	1211	occlusion	occlusion	NN	I-NP
O	1211	1212	.	.	.	O

O	1213	1216	The	The	DT	B-NP
B-Cell	1217	1221	cell	cell	NN	I-NP
O	1222	1228	injury	injury	NN	I-NP
O	1229	1236	induced	induce	VBN	B-VP
O	1237	1239	by	by	IN	B-PP
O	1240	1243	the	the	DT	B-NP
O	1244	1252	nonionic	nonionic	JJ	I-NP
O	1253	1266	radiocontrast	radiocontrast	NN	I-NP
O	1267	1273	medium	medium	NN	I-NP
O	1274	1282	ioversol	ioversol	NN	I-NP
O	1283	1286	was	be	VBD	B-VP
O	1287	1295	reversed	reverse	VBN	I-VP
O	1296	1298	by	by	IN	B-PP
O	1299	1309	inhibiting	inhibit	VBG	B-VP
O	1310	1312	de	de	FW	B-NP
O	1313	1317	novo	novo	FW	I-NP
O	1318	1326	ceramide	ceramide	NN	I-NP
O	1327	1336	synthesis	synthesis	NN	I-NP
O	1337	1341	with	with	IN	B-PP
O	1342	1351	fumonisin	fumonisin	NN	B-NP
O	1352	1353	B	B	NN	I-NP
O	1353	1354	(	(	(	O
O	1354	1355	1	1	CD	B-NP
O	1355	1356	)	)	)	O
O	1357	1358	(	(	(	O
O	1358	1360	FB	FB	NN	B-NP
O	1360	1361	(	(	(	O
O	1361	1362	1	1	CD	B-NP
O	1362	1363	)	)	)	O
O	1363	1364	)	)	)	O
O	1365	1368	and	and	CC	O
O	1369	1370	L	L	NN	B-NP
O	1370	1371	-	-	HYPH	O
O	1371	1382	cycloserine	cycloserine	NN	B-NP
O	1382	1383	,	,	,	O
O	1384	1387	but	but	CC	O
O	1388	1391	not	not	RB	B-PP
O	1392	1394	by	by	IN	I-PP
O	1395	1406	suppressing	suppress	VBG	B-VP
O	1407	1420	sphingomyelin	sphingomyelin	NN	B-NP
O	1421	1430	breakdown	breakdown	NN	I-NP
O	1431	1435	with	with	IN	B-PP
O	1436	1440	D609	D609	NN	B-NP
O	1440	1441	.	.	.	O

O	1442	1444	FB	FB	NN	B-NP
O	1444	1445	(	(	(	O
O	1445	1446	1	1	CD	B-NP
O	1446	1447	)	)	)	O
O	1448	1456	reversed	reverse	VBD	B-VP
O	1457	1465	ioversol	ioversol	NN	B-NP
O	1465	1466	-	-	HYPH	B-NP
O	1466	1473	induced	induce	VBN	I-NP
O	1474	1482	decrease	decrease	NN	I-NP
O	1483	1485	in	in	IN	B-PP
O	1486	1489	the	the	DT	B-NP
O	1490	1508	immunoreactivities	immunoreactivity	NNS	I-NP
O	1509	1511	of	of	IN	B-PP
O	1512	1516	pAkt	pAkt	NN	B-NP
O	1517	1520	and	and	CC	I-NP
O	1521	1526	pCREB	pCREB	NN	I-NP
O	1526	1527	,	,	,	O
O	1528	1537	reduction	reduction	NN	B-NP
O	1538	1540	in	in	IN	B-PP
O	1541	1544	Bcl	Bcl	NN	B-NP
O	1544	1545	-	-	HYPH	B-NP
O	1545	1546	2	2	CD	I-NP
O	1547	1557	expression	expression	NN	I-NP
O	1558	1561	and	and	CC	O
O	1562	1569	caspase	caspase	NN	B-NP
O	1569	1570	-	-	HYPH	O
O	1570	1571	3	3	CD	B-NP
O	1572	1582	activation	activation	NN	I-NP
O	1582	1583	.	.	.	O

O	1584	1588	Like	Like	IN	B-PP
O	1589	1597	ioversol	ioversol	NN	B-NP
O	1597	1598	,	,	,	O
O	1599	1601	C2	C2	NN	B-NP
O	1602	1610	ceramide	ceramide	NN	I-NP
O	1611	1614	and	and	CC	O
O	1615	1618	the	the	DT	B-NP
O	1619	1622	Akt	Akt	NN	I-NP
O	1623	1632	inhibitor	inhibitor	NN	I-NP
O	1633	1636	Src	Src	NN	I-NP
O	1637	1645	homology	homology	NN	I-NP
O	1645	1646	-	-	HYPH	B-NP
O	1646	1647	6	6	CD	I-NP
O	1648	1655	induced	induce	VBN	I-NP
O	1656	1665	apoptosis	apoptosis	NN	I-NP
O	1666	1668	by	by	IN	B-PP
O	1669	1677	reducing	reduce	VBG	B-VP
O	1678	1682	pAkt	pAkt	NN	B-NP
O	1683	1686	and	and	CC	I-NP
O	1687	1692	pCREB	pCREB	NN	I-NP
O	1692	1693	-	-	HYPH	B-NP
O	1693	1697	like	like	JJ	I-NP
O	1698	1716	immunoreactivities	immunoreactivity	NNS	I-NP
O	1716	1717	,	,	,	O
O	1718	1726	lowering	lower	VBG	B-VP
O	1727	1730	Bcl	Bcl	NN	B-NP
O	1730	1731	-	-	HYPH	O
O	1731	1732	2	2	CD	B-NP
O	1733	1743	expression	expression	NN	I-NP
O	1744	1747	and	and	CC	O
O	1748	1757	enhancing	enhance	VBG	B-VP
O	1758	1765	caspase	caspase	NN	B-NP
O	1765	1766	-	-	HYPH	O
O	1766	1767	3	3	CD	B-NP
O	1768	1776	activity	activity	NN	I-NP
O	1776	1777	.	.	.	O

O	1778	1784	Indeed	Indeed	RB	B-ADVP
O	1784	1785	,	,	,	O
O	1786	1793	various	various	JJ	B-NP
O	1794	1807	radiocontrast	radiocontrast	NN	I-NP
O	1808	1813	media	medium	NNS	I-NP
O	1813	1814	,	,	,	O
O	1815	1824	excluding	exclude	VBG	B-PP
O	1825	1834	iodixanol	iodixanol	NN	B-NP
O	1835	1840	which	which	WDT	B-NP
O	1841	1847	showed	show	VBD	B-VP
O	1848	1851	the	the	DT	B-NP
O	1852	1857	least	least	JJS	I-NP
O	1858	1872	nephrotoxicity	nephrotoxicity	NN	I-NP
O	1872	1873	,	,	,	O
O	1874	1882	enhanced	enhance	VBD	B-VP
O	1883	1891	ceramide	ceramide	NN	B-NP
O	1891	1892	-	-	HYPH	B-NP
O	1892	1896	like	like	JJ	I-NP
O	1897	1913	immunoreactivity	immunoreactivity	NN	I-NP
O	1913	1914	.	.	.	O

O	1915	1918	The	The	DT	B-NP
O	1919	1923	role	role	NN	I-NP
O	1924	1927	for	for	IN	B-PP
O	1928	1930	de	de	FW	B-NP
O	1931	1935	novo	novo	FW	I-NP
O	1936	1944	ceramide	ceramide	NN	I-NP
O	1945	1954	synthesis	synthesis	NN	I-NP
O	1955	1958	was	be	VBD	B-VP
O	1959	1963	also	also	RB	I-VP
O	1964	1969	shown	show	VBN	I-VP
O	1970	1972	in	in	IN	B-PP
O	1973	1976	the	the	DT	B-NP
O	1977	1979	in	in	FW	I-NP
O	1980	1984	vivo	vivo	FW	I-NP
O	1985	1990	model	model	NN	I-NP
O	1991	1993	of	of	IN	B-PP
O	1994	2007	radiocontrast	radiocontrast	NN	B-NP
O	2008	2019	nephropathy	nephropathy	NN	I-NP
O	2019	2020	.	.	.	O

O	2021	2023	We	We	PRP	B-NP
O	2024	2036	demonstrated	demonstrate	VBD	B-VP
O	2037	2041	here	here	RB	B-ADVP
O	2042	2045	for	for	IN	B-PP
O	2046	2049	the	the	DT	B-NP
O	2050	2055	first	first	JJ	I-NP
O	2056	2060	time	time	NN	I-NP
O	2061	2065	that	that	IN	B-ADVP
O	2066	2069	the	the	DT	B-NP
O	2070	2081	enhancement	enhancement	NN	I-NP
O	2082	2084	of	of	IN	B-PP
O	2085	2087	de	de	FW	B-NP
O	2088	2092	novo	novo	FW	I-NP
O	2093	2101	ceramide	ceramide	NN	I-NP
O	2102	2111	synthesis	synthesis	NN	I-NP
O	2112	2123	contributes	contribute	VBZ	B-VP
O	2124	2126	to	to	TO	B-PP
O	2127	2140	radiocontrast	radiocontrast	NN	B-NP
O	2141	2152	nephropathy	nephropathy	NN	I-NP
O	2152	2153	.	.	.	O

